UCB's Keppra patent litigation in the US settled
UCB announced that it has reached agreement with each of Mylan laboratories and Mylan Pharmaceuticals, Dr. Reddy's Laboratories and cobalt Pharmaceuticals to settle pending patent infringement lawsuits in the U.S. District Court for the Northern District of Georgia.
These consolidated lawsuits involve the patent (the '639 patent) for levetiracetam, the active ingredient in UCB's anti-epilepsy product, Keppra®.
Under the terms of the settlement agreement with Mylan, and subject to its receiving FDA approval, Mylan will be allowed to sell its generic levetiracetam tablets effective November 1, 2008, in advance of the anticipated expiry of UCB's market exclusivity on January 14, 2009 (subject to grant of paediatric exclusivity under the '639 patent).
The parties have agreed to maintain as confidential the remaining terms of the Mylan settlement agreement and those with Dr. Reddy's and Cobalt.
The settlement arrangements are subject to mandated review by the US anti trust authorities.
This settlement of the lawsuits in a mutually beneficial manner was achieved following a mediation process at the encouragement of the Court and will enable the parties to focus their efforts on the conduct of their respective businesses.
Other news from the department business & finance
These products might interest you
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
